Newsletter

Int. Rev. Allergol. Clin. Immunol. F-amily Med., 2018, XXIV/3: 113-118 Maximize

Int. Rev. Allergol. Clin. Immunol. F-amily Med., 2018, XXIV/3: 113-118

Title: Azithromycin in therapy of patients with communityacquired pneumonia 

Authors: Płusa T, Bijoś P. 

More details

04-03-2018

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Azithromycin in therapy of patients with communityacquired pneumonia


Płusa T1, Bijoś P2.

1Medical Faculty of Łazarski University of Warsaw, Poland; 2Teva Pharmaceuticals Polska

Int Rev Allergol Clin Immunol Family Med, 2018; Vol. 24, No. 3, 113

The choice of an antibiotic in the treatment of patients with communityacquired pneumonia should be based on the pharmacokinetic data of the preparation and its antibacterial spectrum. In many clinical situations, the presence of atypical bacteria in addition to a typical infection requires the administration of an antibiotic having the ability to penetrate inside the macrophage and to the pulmonary parenchyma, where the inflammatory process is going on. Azithromycin meets these criteria and is therefore increasingly used. The effectiveness of such proceedings is confirmed by the analyzes of multicentre studies. The effectiveness of azithromycin, both in monotherapy and in combination with other antibiotics, is significantly higher than the antibiotics used so far. The inclusion of the possibility of administering azithromycin in the form of inhalation microparticles can significantly change the effectiveness of treatment of patients with community-acquired pneumonia.

Key words: community-acquired pneumonia, azithromycin